October 26, 2016 7:25 PM ET


Company Overview of FORUM Pharmaceuticals Inc.

Company Overview

FORUM Pharmaceuticals Inc. is a pharmaceutical company that focuses on discovering and developing new treatments for neuropsychiatric conditions. The company focuses on brain diseases, such as schizophrenia, Alzheimer’s disease, and frontotemporal dementia. Its pipeline includes Encenicline - agonist of alpha 7 receptor response; FRM-0334, an orally bioavailable, small molecule inhibitor of histone deacetylase enzymes for the treatment of patients with frontotemporal dementia associated with genetic mutation of the granulin gene, known as FTD-GRN; FRM-6308, a treatment for positive, negative, and cognitive symptoms in patients with acute and chronic schizophrenia; next-generation alpha 7 ago...

225 Second Avenue

Watertown, MA 02472

United States

Founded in 2001





Key Executives for FORUM Pharmaceuticals Inc.

Chief Executive Officer, President and Director
Age: 53
Senior Vice President and General Counsel
Chief Business Officer and Senior Vice President
Age: 54
Chief Medical Officer and Senior Vice President of Clinical Development
Age: 63
Senior Vice President of Quality, Technical Operations, Program & Alliance Management
Compensation as of Fiscal Year 2016.

FORUM Pharmaceuticals Inc. Key Developments

FORUM Pharmaceuticals Inc. Presents at Boston CEO Conference, May-31-2016 08:00 AM

FORUM Pharmaceuticals Inc. Presents at Boston CEO Conference, May-31-2016 08:00 AM. Venue: Four Seasons Boston, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Deborah Dunsire, Chief Executive Officer, President and Director.

FORUM Pharmaceuticals Inc. Provides Update on Encenicline Phase 3 Clinical Trial Program in Cognitive Impairment in Schizophrenia

FORUM Pharmaceuticals Inc. announced topline results from two Phase 3 clinical trials in patients with cognitive impairment in schizophrenia (CIS). While encenicline (FRM-6124) demonstrated a favorable safety and tolerability profile in both studies, neither study met its co-primary endpoints based on effect on cognitive function and patient function. An unexpectedly high placebo response was observed in both trials. Activity was observed across certain sub-groups and secondary endpoints, and these results are being further analyzed. FORUM expects to share further data from both studies at a future scientific meeting. In conjunction with this update and the ongoing data analyses, the company is implementing a significant restructuring of its organization to appropriately scale its spending and resources and to evaluate a potential path forward, if any. About the Encenicline Phase 3 Clinical Trial Program in Cognitive Impairment in Schizophrenia (CIS): The encenicline Phase 3 program in CIS includes two parallel, randomized, double-blind, placebo-controlled studies (015 and 016) evaluating the safety and efficacy of two oral doses of once daily treatment with encenicline as a pro-cognitive treatment compared to placebo when added to atypical antipsychotic therapy in people with schizophrenia. More than 750 patients were evaluated in each study over 26 weeks across 200 sites. Primary Endpoints: effect on cognitive function as measured by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Neurocognitive Composite Score, and effect on patient function as measured by the interview-based Schizophrenia Cognition Rating Scale (SCoRS). Secondary Endpoints: clinical efficacy as measured by the negative subscale of the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression – Severity (CGI-S), Clinical Global Impression – Change Scale (CGI-C), and quality of life, using the EuroQoL5D (EQ-5D).

Forum Pharmaceuticals Plans to Lay Off Up to 89 Employees

Forum Pharmaceuticals has notified the state that it will lay off as many as 89 employees in coming months after a late-stage trial of its lead drug for Alzheimer's disease and schizophrenia was halted for two months last year by the Food and Drug Administration. Forum submitted a letter to the Massachusetts Division of Career Services dated March 21 outlining plans to lay off 77 employees during the 30-day period beginning May 20. The letter said that all employees affected have already been notified. Another 12 employees could be laid off "if the company receives adverse clinical trial data".

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact FORUM Pharmaceuticals Inc., please visit www.forumpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.